Citigroup Inc. Reiterates Buy Rating for AstraZeneca plc (LON:AZN)
Citigroup Inc. reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Friday morning, MarketBeat reports. The firm currently has a GBX 6,000 ($79.15) price objective on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the company. Kepler Capital Markets reissued a buy rating and issued a GBX 5,000 ($65.95) target price on shares of AstraZeneca plc in a research note on Friday, April 21st. Deutsche Bank AG reissued a buy rating and issued a GBX 5,500 ($72.55) target price on shares of AstraZeneca plc in a research note on Friday, April 7th. Morgan Stanley reissued a buy rating on shares of AstraZeneca plc in a research note on Monday, April 24th. Liberum Capital reissued a buy rating and issued a GBX 5,100 ($67.27) target price on shares of AstraZeneca plc in a research note on Thursday, April 27th. Finally, Berenberg Bank set a GBX 5,670 ($74.79) target price on AstraZeneca plc and gave the company a buy rating in a research note on Thursday, April 27th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. AstraZeneca plc currently has a consensus rating of Hold and a consensus target price of GBX 5,046.95 ($66.57).
Shares of AstraZeneca plc (LON AZN) opened at 4571.00 on Friday. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 5,140.37 and a 200 day moving average price of GBX 4,864.62. The firm’s market cap is GBX 57.87 billion.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/citigroup-inc-reiterates-buy-rating-for-astrazeneca-plc-lonazn/1464798.html.
The company also recently declared a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be issued a GBX 68.90 ($0.91) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.35%.
In other news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($57.64) per share, for a total transaction of £1,704.30 ($2,248.12).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.